

INTERNATIONAL PRIZE FOR SCIENTIFIC RESEARCH ARRIGO RECORDATI 2024

Andrew Pearson **M.D., Ph.D.,**

**Retired Cancer Research UK Professor
of Paediatric Oncology, Institute of Cancer
Research and the Royal Marsden
Hospital NHS Trust, Sutton, UK**



Prof Andy Pearson is formerly a Cancer Research UK Professor of Paediatric Oncology, at the Institute of Cancer Research and the Royal Marsden Hospital NHS Trust. In May 2014 he retired due to ill health from The Institute of Cancer Research and Royal Marsden NHS Foundation Trust. Prior to 2005, he had been a Professor of Paediatric Oncology, at the University of Newcastle upon Tyne and Dean of Postgraduate Studies, Faculty of Medical Sciences, at the University of Newcastle upon Tyne. Professor Pearson trained at Newcastle upon Tyne and was Lilly International/Medical Research Council Travelling Fellow at the University of Minnesota, USA.

Professor Andy Pearson expertise is in the fields of drug development and neuroblastoma and has over 45 years' experience in clinical paediatric oncology. He was the first Chair of the United Kingdom Children Cancer Study Group (UKCCSG) Neuroblastoma Group, Chair of the European Neuroblastoma Group, and was the founding chair of the International Society of Paediatric Oncology Europe Neuroblastoma Group (SIOPEN). He is on the Advisory Board of SIOPEN. He and Professor Sue Cohn of Chicago created and chair the International Neuroblastoma Risk Group Consortium (INRG). He was President of the Advances in Neuroblastoma Research Association from 2012 - 2014 and was on the ANRA Advisory Board for Europe and Russia since 2006. He was Chairman of the UKCCSG from 2003 - 2006. Professor Pearson was the Chief Investigator of the clinical trial ENSG 5 which changed the standard practice for the therapy of high-risk neuroblastoma in Europe. He was the first Chief Investigator of the BEACON Trial; the first randomized European study for refractory/relapsed neuroblastoma. He has published over 400 scientific manuscripts. Professor Pearson led the first paediatric phase I study in the UK. He has been involved in the pre-clinical and early clinical development of many anti-cancer agents in children. He is a member of the Executive of the Innovative Therapy for Children with Cancer Consortium (ITCC). He is a Chair of ACCELERATE, EMA, and FDA Paediatric Strategy Forum Oversight Committee, Senior Advisor, and member of the Steering Committee of the ACCELERATE to improve drug development for children and adolescents with cancer. He was Chair of the National Cancer Research Institute Children's Cancer and Leukaemia Clinical Studies Group Novel Agents Subgroup and a member of the New Agents Committee of Cancer Research UK. He led a comprehensive paediatric drug development program, with one of the largest portfolios of early phase, first in child, biomarker rich studies in Europe at The Institute of Cancer Research and Royal Marsden focusing on neuroblastoma. He has published over 400 scientific manuscripts.

Professor Pearson is chair of Solving Kids Cancer Scientific Advisory Board and Patron and Trustee of Neuroblastoma UK and a member of the Programme Committee of Fight Kids Cancer. He was awarded a Life Time Achievement Award from Advances in Neuroblastoma Research in 2016.